NVAX Stock Overview
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.95 |
| 52 Week High | US$11.36 |
| 52 Week Low | US$3.53 |
| Beta | 1.6 |
| 1 Month Change | -16.14% |
| 3 Month Change | -2.71% |
| 1 Year Change | -47.75% |
| 3 Year Change | -98.34% |
| 5 Year Change | -62.53% |
| Change since IPO | -95.06% |
Recent News & Updates
Recent updates
Novavax: Another Day Older And Deeper In
Mar 02Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Mar 01Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems
Feb 23Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel
Sep 06Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook
Mar 05COVID-19 remains global health emergency - WHO
Oct 19Shareholder Returns
| NVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.5% | 0.4% | 1.0% |
| 1Y | -47.8% | 0.9% | 21.9% |
Return vs Industry: NVAX underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: NVAX underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months.
Volatility Over Time: NVAX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | US$552.81m |
| Earnings (TTM) | -US$545.06m |
| Revenue (TTM) | US$983.71m |
0.6x
P/S Ratio-1.0x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$983.71m |
| Cost of Revenue | US$1.08b |
| Gross Profit | -US$94.76m |
| Other Expenses | US$450.30m |
| Earnings | -US$545.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.89 |
| Gross Margin | -9.63% |
| Net Profit Margin | -55.41% |
| Debt/Equity Ratio | -23.4% |
How did NVAX perform over the long term?
See historical performance and comparison